A total of 38 NSCLC cases (76%) had ≥ 1 alteration detectable, of which TP53 mutations were most prevalent (60.5%), followed by mutations in clinically actionable target genes, EGFR (31.6%), BRAF (13.2%), KRAS (10.5%), and MET (7.9%). This evidence concerns the gene TP53 and non-small cell lung carcinoma.